Earnings Call Intelligence Subscribe
Home › Call Sheets › JNJ › Q4'25
Call sheet · Q4'25

Johnson & Johnson (JNJ)

Q4'25 earnings call · held January 21, 2026 · compared with the Q3'25 call · management-credibility review
10/12
Disclosure score
6 low flags
Financial quality
Bottom line
The sleeper story is that JNJ quietly became the first healthcare company to guide $100B revenue while the market fixated on STELARA erosion. The post-STELARA business is growing double-digits with 13 brands hitting double-digit growth. The binding constraint isn't demand but execution bandwidth - they're launching Tremfya IBD, icotide, Ottava robotics, and Inlexo expansion simultaneously while absorbing $500M in tariff headwinds. Joaquin's most revealing quote: 'We do not need large M&A to deliver in the high end of our growth targets' - repeated twice for emphasis. My view changes if TREMFYA growth decelerates below 40% or if they push out the double-digit growth timeline beyond 2030.

The 30-second version

  • The sleeper story: JNJ quietly became a $100B revenue company while everyone obsessed over STELARA erosion
  • Double-digit growth 'by end of decade' claim lacks specifics but pipeline depth is real
  • Margin guidance absorbs $500M in new tariff headwinds but still promises 50bps improvement

What changed this quarter

MetricQ3'25Q4'25Change
Revenue$24.0B (+5.4% YoY)$24.6B (+7.1% YoY)+170bps acceleration to 7.1%
Adjusted EPS$2.42$2.46 (+21.5% YoY)Beat by $0.04
Innovative Medicine Revenue$15.0B (+5.3%)$15.8B (+7.9%)+260bps acceleration despite STELARA headwinds
MedTech Revenue$8.4B (+5.6%)$8.8B (+5.8%)+20bps to 5.8% growth
DARZALEX Growth19.9%24.1%+420bps acceleration
TREMFYA Growth40.1%65.4%+2,530bps acceleration to 65%
STELARA Decline-42%-48.6%Erosion accelerated 660bps
CARVICTI Revenue$524M (+81.4%)$555M (+63.2%)Growth decelerated 1,820bps
Operating Margin24.1%28.7%+460bps improvement
Free Cash Flow (YTD)$14B through Q3$19.7B full yearMaintained $19.7B generation

Accountability tracked

8 new promises made4 narrative shifts flagged6 prior promises scored
Inside the full report
The complete write-up covers the full promise ledger with kept/missed calls, disclosure-quality scoring, the metrics-vanished check, verification items, and the questions to ask next quarter.
Read the full JNJ Q4'25 report Subscribe
About Research ↗Call SheetsCredibility IndexMissed PromisesScreens13F BooksData & InstitutionalPrivacyTermsSubscribe
This is a free preview. The full write-up and promise ledger are published to subscribers on Substack.
Scores, kept-promise rates, and flags on this site reflect the author's opinion, applying a stated methodology to statements management made on public earnings calls. Informational and educational purposes only - not investment advice, a recommendation, or an offer to buy or sell any security. Sources believed reliable but not guaranteed; the author may hold positions in the securities discussed.

Follow what management promises next

Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.

Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.